Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.

Compared with the ADNI-1-matched cohort, subjects on ALZ-801 showed a trend to decreased atrophy at 52 weeks ( p = 0.109) that became statistically significant at 104 weeks ( p = 0.0014), as shown in Fig. 4 .

also in 53,322 other papers

In the same tramiprosate study, the effects on the APOE3/4 heterozygote subjects showed nominally significant effects on the composite cognitive/functional Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ 47 ], but the cognitive effects were less pronounced.

also in 7,732 other papers